Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols
Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols
复制标题
DOI：
10.1111/j.1542-4758.2011.00642.x
复制
发表时间：
2012-04-01
影响因子：
1.3
通讯作者：
Block, Geoffrey A.
中科院分区：
文献类型：
--
作者：
Chertow, Glenn M.;Lu, Z. John;Block, Geoffrey A.
继发性甲状旁腺功能亢进的患者会出现多种临床症状，可能会对身体和精神功能产生不利影响。作为多中心、开放标签临床试验的一部分，受试者在研究期间的多个时间点完成了一份问卷，其中包括医学结局研究简表-36和14种肾脏疾病相关症状。在接受至少一剂西那卡塞的567例受试者中，528 - 535例（93.894.4%）在基线时完成了问卷的全部或部分。甲状旁腺激素（PTH）的中位数为294？pg/mL（10%，90%范围，172655？pg/mL）。在用西那卡塞和低剂量维生素D固醇治疗后，受试者报告肌肉、关节和骨骼疼痛、关节僵硬、皮肤干燥、皮肤瘙痒、过度口渴和记忆障碍的频率显著改善。在疗效评估阶段结束时（第16至22周），关节疼痛、骨痛、皮肤干燥和过度口渴的改善幅度最大（0100量表>5; P？
Patients with secondary hyperparathyroidism experience a variety of clinical symptoms which may adversely affect physical and mental function. As part of a multicenter, open-label clinical trial, subjects completed a questionnaire that included the Medical Outcomes Study Short Form-36 and 14 kidney disease-related symptoms at multiple time points during the study. Out of the 567 subjects who received at least one dose of cinacalcet, 528 to 535 (93.894.4%) completed all or portions of the questionnaire at baseline. The median bioactive parathyroid hormone (PTH) was 294?pg/mL (10%, 90% range, 172655?pg/mL). Following treatment with cinacalcet and low-dose vitamin D sterols, subjects reported significant improvement in the frequency of pain in muscles, joints and bones, stiff joints, dry skin, itchy skin, excessive thirst, and trouble with memory. At end of the efficacy assessment phase (Weeks 16 to 22), the magnitude of improvement was the greatest in joint pain, bone pain, dry skin, and excessive thirst (>5 on a 0100 scale; P?